Scancell
Phase 3Scancell is a clinical stage immunotherapy biotech developing treatments for significant unmet needs in cancer.
Founded
1996
Focus
Vaccines
About
Scancell is a clinical stage immunotherapy biotech developing treatments for significant unmet needs in cancer.
Funding History
4Total raised: $51M
Series C$25MLife Sciences PartnersNov 15, 2020
Grant$2.5MInnovate UKMar 15, 2018
Series B$15MRedx PharmaJun 15, 2015
Series A$8.5MIP GroupJan 15, 2012
Company Info
TypePrivate
Founded1996
LocationNottingham, United Kingdom
StagePhase 3
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile